COVID-19

Although pharmaceutical companies have already begun developing COVID-19 vaccine boosters, Michael Haydock of Informa Pharma Intelligence said boosters may not be necessary in the fall of 2021.

The preprint submitted by the company consists of a new analysis from blood samples obtained from a subset of participants in the phase 3 ENSEMBLE study.

The investigators also found that the risk of spreading disease may be lower amongst those with breakthrough infections.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed what some of the adverse events experienced by patients were, and how patients were able to handle them.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the research assessing dapagliflozin advanced from cardiorenal effects to prevention and organ protection.

The study evaluated vaccination trends among adults aged 18 years or older using data from the CDC, comparing the rates in Ohio before and after the implementation of the lottery with states that did not have lottery programs.

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the results of the DARE-19 trial are important to the field, especially during the COVID-19 pandemic.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed how the phase 3 DARE-19 trial was conducted to assess dapagliflozin in patients with type 2 diabetes hospitalized with COVID-19.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the safety profile of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19 during the DARE-19 trial.

Debate and discussion about the origin of the virus that causes COVID-19 have been at the forefront of global consciousness since the first cases were reported in December 2019.

Greater risk for heart damaged come from coronavirus infection, and patients should not be discouraged from vaccination.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the efficacy of dapagliflozin in the DARE-19 trial assessing its efficacy and safety in patients with type 2 diabetes hospitalized with COVID-19.

The COVID-19 pandemic has led to significant innovation, which presents a unique opportunity for pharmacists to advance pharmacy practice by serving as the integral drug monitoring experts of the health care team.

Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, discusses upcoming clinical trials on COVID-19 booster shots, the possibility of cancer vaccines, and the future of pharmaceuticals and FDA approvals.

Investigators found that a single initial dose may be sufficient for patients with prior infection.

The research team discovered that community pharmacists, as a skilled clinical workforce, could positively contribute to the future of COVID-19 vaccination programs by continuing to be active in COVID-19 vaccination campaigns.

From Tuesday, June 22 to Saturday, June 26, customers getting a COVID-19 vaccination at Walgreens pharmacies will receive $25 in Walgreens cash rewards for in-store purchases.

Previous trials in non-hospitalized patients with COVID-19 suggested casirivimab and imdevimab reduced viral levels, shortened the time to resolution of symptoms and significantly reduced the risk of hospitalization or death.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

The findings showed that 63 of the 9119 patients with severe COVID-19 infection contracted the virus a second time, with an average reinfection period of 116 days.

A lower antibody response found in one-fourth of patients taking methotrexate does not necessarily mean that these patients are not protected against COVID-19.

New protocol for processing saliva samples with a bead mill homogenizer before real-time PCR testing has shown higher sensitivity to COVID-19 than nasopharyngeal swab testing

The investigators created a panel of pseudotype viruses, which combined the HIV virus and SARS-CoV-2 spike protein.

The Novavax COVID-19 vaccine NVX-CoV2373 demonstrated 100% protection against moderate and severe disease and 90.4% efficacy overall in a phase 3 trial.